DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cor pulmonale — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCor pulmonale maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cor pulmonale is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
In 1950 a single case of acute cor pulmonale in a 22-year-old man was reported, but the authors noted the condition is seldom diagnosed, partly because it can be transient or confused with other diseases. By 1966 data on 52 patients with cor pulmonale had been collected, and the condition was defined as a cardiovascular disorder secondary to chronic pulmonary disease involving hypoxaemia, carbon dioxide retention, polycythaemia, and right ventricular hypertrophy and failure. A 2003 review stated that cor pulmonale is itself a cause of significant morbidity and mortality and that it adversely affects the natural history of many causative lung disorders; it also noted that clinical, laboratory, and radiographic findings are relatively insensitive, complicating diagnosis and management. A 2025 source reiterates that cor pulmonale is usually chronic but can be acute and reversible, and it excludes left ventricular failure, congenital heart defects, and secondary right ventricular dilatation from acquired valvular disease.
A 1958 report described two cases of subacute cor pulmonale due to thrombosis of the pulmonary artery trunk and major branches. The first case, a 62-year-old woman, was used to argue that accurate clinical diagnosis and surgical management might be possible. The second case was presented as the first planned surgical attempt to relieve the obstructive phase of chronic cor pulmonale from pulmonary artery thrombosis. No survival or functional outcomes for either patient were given in the abstract.
The 2003 review summarises that pulmonary hypertension is the primary cardiovascular complication in COPD and that its development reduces survival rate in COPD. It also states that in cystic fibrosis, secondary pulmonary hypertension and cor pulmonale are likely to develop as lung disease progresses, and that pulmonary hypertension increases the risk of death in affected patients. The review covers surgical management of chronic thromboembolic pulmonary hypertension, noting that recent progress has improved the once dismal prognosis, but it provides no numerical survival or response data in the abstract.
What is still missing is any randomised controlled trial of a drug specifically for cor pulmonale, any prospective data on how modern diagnostic methods change patient outcomes, and any stratification of patients by the underlying lung disease to guide therapy. No drug is mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Internal Medicine · 1958 · 16 citations
The Clinical and Surgical Aspects of Chronic Pulmonary Artery Thrombosis
AbstractAn experience with two cases of subacute cor pulmonale due to thrombosis of the trunk and major branches of the pulmonary artery has brought into focus the possibility of a surgical approach to the treatment of this disease. The clinical and anatomic features of the first case suggested the possibility of making an accurate clinical diagnosis and of managing the problem surgically. The second case report represents the first planned attempt surgically to relieve the obstructive phase of chronic cor pulmonale due to pulmonary artery thrombosis. <h3>Report of Cases</h3><h3>Case 1.</h3> —A 62-year-old white woman was admitted for the second time to Montefiore Hospital on Jan. 11, 1956, because of severe and increasing dyspnea of approximately 10 hours' duration. She was initially admitted on Dec. 16, 1955, because of an enlarged obstructing thyroid gland which compressed the right recurrent laryngeal nerve. On Dec. 29, 1955, a subtotal thyroidectomy was performed.
AbstractCase Reports1 October 1950ACUTE COR PULMONALEIRA L. RUBIN, M.D., GERALD FLAUM, M.D, F.A.C.P.IRA L. RUBIN, M.D., GERALD FLAUM, M.D, F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-33-4-1013 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPulmonary infarction is a relatively common condition, but acute cor pulmonale is seldom diagnosed. This may be due to the transient nature of the process, or to confusion with other disease states. The purpose of this report is to present an interesting case of acute cor pulmonale and to draw attention to the confusion in the diagnosis of this condition.1CASE REPORTA 22 year old white bricklayer was admitted with chief complaint of severe sharp pain in the left lumbar region of one day's duration. His past history included a duodenal ulcer while in military service in April, 1945....Bibliography1. Myers WK: Penicillin therapy of gonococcic endocarditis of the pulmonary valve, J. A. M. A. 133: 1205, 1947. CrossrefMedlineGoogle Scholar2. White PD: The acute cor pulmonale, Ann. Int. Med. 9: 115, 1935. LinkGoogle Scholar3. McGinnWhite SPD: Acute cor pulmonale resulting from pulmonary embolism, J. A. M. A. 104: 1473, 1935. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication April 3, 1948.From the Medical Division, Veterans Hospital, Kingsbridge Road, Bronx, N. Y.Published with permission of the Chief Medical Director, Department of Medicine and Surgery, Veterans Administration, who assumes no responsibility for the opinions expressed or conclusions drawn by the authors. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCor pulmonale caused by recurrent pulmonary emboliSubacute cor pulmonale 1 October 1950Volume 33, Issue 4Page: 1013-1016KeywordsArmed forcesDuodenal ulcersHospital medicineInfarctionSurgery Issue Published: 1 October 1950 PDF downloadLoading ...
AbstractCor pulmonale is a specific cardiovascular disorder secondary to chronic pulmonary disease in which there is hypoxemia, chronic carbon dioxide retention, polycythemia and right ventricular hypertrophy and failure. Aids to diagnosis are x-rays of the thorax, electrocardiograms, pulmonary function tests, and Astrup determinations. Data are presented on 52 patients with cor pulmonale.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ADVANTAGES OF MODERN CLINICAL DIAGNOSTIC METHODS FOR CARDIOVASCULAR DISEASES
AbstractCor pulmonale results from pathology of the lungs or their vessels; it does not include left ventricular (LV) failure, congenital heart defects (eg, ventricular septal defect), or secondary right ventricular (RV) dilatation due to acquired valvular pathology. Cor pulmonale is usually a chronic condition, but it can be acute and reversible. Primary pulmonary hypertension (i.e., not caused by lung or heart disease) is discussed elsewhere.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ADVANTAGES OF MODERN CLINICAL DIAGNOSTIC METHODS FOR CARDIOVASCULAR DISEASES
AbstractCor pulmonale results from pathology of the lungs or their vessels; it does not include left ventricular (LV) failure, congenital heart defects (eg, ventricular septal defect), or secondary right ventricular (RV) dilatation due to acquired valvular pathology. Cor pulmonale is usually a chronic condition, but it can be acute and reversible. Primary pulmonary hypertension (i.e., not caused by lung or heart disease) is discussed elsewhere.
Seminars in Respiratory and Critical Care Medicine · 2003 · 0 citations
Cor Pulmonale and Heart-Lung Interactions
AbstractCor pulmonale is the alteration in the structure and function of the right ventricle that results from pulmonary artery hypertension caused by various disorders affecting the lung. Cor pulmonale is itself a cause of significant morbidity and mortality and adversely affects the natural history of many of these causative disorders. The clinical manifestations of cor pulmonale as well as the laboratory and radiographic findings are relatively insensitive, thereby complicating its diagnosis and management. In this issue we provide an up-to-date review of cor pulmonale, emphasizing advances in its diagnosis and therapy. The initial overview of cor pulmonale by Drs. Budev, Arroliga, Wiedemann, and Matthay, along with the subsequent article by Drs. Kosiborod and Wackers on the assessment of right ventricular morphology and function, establish the background and context for the subsequent discussion of the clinical entities that are associated with pulmonary hypertension and cor pulmonale. The overview by Budev and colleagues discusses the pathophysiology of pulmonary hypertension, right ventricular anatomy and physiology, and the interaction of the right and left ventricle in cor pulmonale. Drs. Kosiborod and Wackers elucidate some recent advances in echocardiography and radionuclide and magnetic resonance imaging that enable clinicians to assess accurately and noninvasively the structure and function of the right ventricle. Following these two introductory articles are seven reviews that focus primarily on the epidemiology, etiology, manifestations, evaluation, and therapy of the clinical disorders complicated by cor pulmonale. The first such article, by Drs. Lee-Chiong and Matthay, discusses cor pulmonale in chronic obstructive pulmonary disease (COPD). This article emphasizes that pulmonary hypertension is the primary cardiovascular complication in COPD and that the development of pulmonary hypertension and cor pulmonale reduces the survival rate in COPD. Dr. Fedullo and colleagues discuss recent progress in the surgical management and postoperative care of patients with chronic thromboembolic pulmonary hypertension. The advances in this rapidly evolving field have helped to improve the once dismal prognosis of this disorder. Dr. Tanoue extensively reviews the relation of collagen vascular diseases and pulmonary artery hypertension, including those disorders, such as scleroderma and mixed connective tissue disease, that have a high prevalence of pulmonary hypertension and other disorders, such as systemic lupus erythematosus and rheumatoid arthritis, that are less commonly associated with pulmonary hypertension. Drs. Krachman, Criner, and Chatila examine the association of obesity, kyphoscoliosis, and such neuromuscular disorders as muscular dystrophy, myotonic dystrophy, poliomyelitis, and myasthenia gravis and the development of cor pulmonale. Dr. Angtuaco provides an excellent synopsis of current information on congenital heart diseases and right ventricular dysfunction. Although cor pulmonale is limited to cardiac dysfunction resulting from pulmonary disease rather than primary cardiac diseases, the manifestations of congenital heart diseases can be indistinguishable from those of pulmonary heart disease. The relationship between sleep disordered breathing and daytime pulmonary hypertension remains controversial. Drs. Judd, Liu, and Sateia discuss recent findings on the physiological changes in the cardiovascular system that occur during sleep disordered breathing. The final article by Drs. Eckles and Anderson reviews cor pulmonale as a complication of cystic fibrosis, emphasizing the pathophysiology, diagnosis, and treatment of heart disease in patients with cystic fibrosis. Secondary pulmonary hypertension and cor pulmonale are likely to develop as lung disease in cystic fibrosis progresses, and pulmonary hypertension increases the risk for death in affected patients. We thank the contributors of this seminar for the excellent texts and the expert counsel they have generously provided us, and we encourage our readers to share with us their thoughts regarding this issue. Richard A. Matthay, M.D. eofilo L. Lee-Chiong Jr., M.D.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
